Letters NICE rejection of prostate cancer drug

The need for preclinical studies of combined modality systemic therapy plus radiotherapy

BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5649 (Published 17 September 2014) Cite this as: BMJ 2014;349:g5649
  1. Ian H Kunkler, consultant in clinical oncology1
  1. 1Edinburgh Cancer Centre, Edinburgh EH4 2XU, UK
  1. i.kunkler{at}ed.ac.uk

The National Institute for Health and Care Excellence’s decision not to recommend abiaterone for men with advanced prostate cancer before chemotherapy, which was based on inadequate evidence of cost effectiveness, illustrates a common challenge for novel anticancer agents.1 Tension exists between the NHS obtaining value for money, patients obtaining access to new drugs, and …

View Full Text

Log in

Log in through your institution


* For online subscription